Tomasina Parker-Actlis

Dr. Tomasina Parker-Actlis


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2025 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
Alan David KayeAlan David Kaye
Alan David Kaye
RIRahib K Islam
Rahib K Islam
INIvan D. Nguyen
Ivan D. Nguyen
CRConnor J. Robin
Connor J. Robin
HNHaley A. Norwood
Haley A. Norwood
SSSahar Shekoohi
Sahar Shekoohi

28 July 2025 in Medical Sciences
Verified
Journal Article
Open access
PDF file
SAShahab Ahmadzadeh
Shahab Ahmadzadeh
BFBennett Ford
Bennett Ford
AHAlex V. Hollander
Alex V. Hollander
MLMary Kathleen Luetkemeier
Mary Kathleen Luetkemeier
TPTomasina Parker-Actlis
Tomasina Parker-Actlis
SSSahar Shekoohi
Sahar Shekoohi
Post-craniotomy pain is common yet often sub-optimally managed because systemic opioids can obscure postoperative neurologic examinations. The superficial cervical plexus block (SCPB) has, therefore, emerged as a targeted regional anesthesia option for occipital craniotomies. The SCPB targets the C2–C4 nerves to anesthetize the occipital scalp region, covering the lesser occipital nerve territory that lies within typical posterior scalp incisions. Clinical evidence shows the block is effective in reducing acute postoperative pain after occipital craniotomy and diminishes opioid requirements. Studies have demonstrated successful and long-lasting analgesia, reductions in 24-h opioid consumption, and a lower incidence of severe pain. Moreover, the technique exhibits a low complication rate and is safer than a deep cervical plexus block because the injection remains superficial and avoids critical vascular and neural structures. When delivered under ultrasound guidance, major adverse events are exceedingly rare. By reducing opioid use, the SCPB can help reduce postoperative complications, allowing earlier neurological assessments and fewer opioid-related side effects. Incorporation of the SCPB into multimodal analgesia regimens can, therefore, accelerate postoperative recovery by providing regionally focused, opioid-sparing pain control without clinically significant sedation. Overall, current data support the SCPB as a dependable, well-tolerated, and clinically practical approach for managing post-craniotomy pain in patients undergoing occipital approaches. In this narrative review, we will discuss the mechanism of action and anatomy, the clinical application, safety and tolerability, patient outcomes, and emerging future directions of the superficial cervical plexus block and how it mitigates post-occipital craniotomy pain.

9 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BEBenjamin Esneault
Benjamin Esneault
MMMacie Maddox
Macie Maddox
ELEthan Michael Loewe
Ethan Michael Loewe
Miguel (Mike) PappollaMiguel (Mike) Pappolla
Miguel (Mike) Pappolla
TPTomasina Parker-Actlis
Tomasina Parker-Actlis
Alan David KayeAlan David Kaye
Alan David Kaye
Traumatic brain injury (TBI) is a major global health problem and a leading cause of long-term neurological disability. TBI produces a spectrum of persistent symptoms, including cognitive impairment, mood and behavioral disturbances, sleep disruption, fatigue, and autonomic dysregulation. Chronic pain is among the most debilitating sequelae, affecting physical, emotional, and social functioning. The etiology of post-TBI pain is multifactorial, arising from initial structural and biochemical injury to the nervous system, maladaptive neuroplastic changes, neuroinflammation, and psychological comorbidities that amplify pain perception and chronicity. This review explores the complex pathophysiology of post-TBI pain and outlines a multidisciplinary framework for management. Pain syndromes are classified according to the International Association for the Study of Pain’s mechanistic framework as nociceptive pain (resulting from tissue injury and inflammation), neuropathic pain (due to lesion or disease of the somatosensory nervous system), and nociplastic pain (arising from altered nociceptive processing without clear evidence of tissue or nerve damage). Many patients exhibit mixed pain phenotypes driven by neuroinflammation and central sensitization. Pharmacologic approaches, including anti-inflammatory agents, anticonvulsants, and antidepressants, require cautious titration due to TBI-related comorbidities. Equally essential are non-pharmacologic strategies such as physical and occupational therapy, cognitive behavioral therapy, and neuromodulation techniques, which target both biomechanical and psychosocial contributors. Emerging innovations, machine learning for prognostication, blood biomarkers for structural injury, and neuro-reparative agents, represent the next frontier in personalized management. Effective care for post-TBI pain requires an integrated strategy that combines mechanistic classification, multidisciplinary treatments, and advancing diagnostic technologies.

25 April 2026 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
SAShahab Ahmadzadeh
Shahab Ahmadzadeh
WMWalid Khaled Mohammed
Walid Khaled Mohammed
SASaajid Zain Azhar
Saajid Zain Azhar
FTFrancis Clay Thompson
Francis Clay Thompson
RBRachael Bartolina
Rachael Bartolina
Alan David KayeAlan David Kaye
Alan David Kaye